Updated on 23 July 2013
PhRMA, that represents large global pharma companies in Washington on the other hand countered this strongly. "Strong intellectual property protections in the TPP to bolster biopharmaceutical innovation will help ensure that unmet patient needs are addressed," the group said.
The group explained that they wanted the US to use TPP negotiations to bring IP standards up to American levels, including at least 12 years of protection for biologies. It argues that intellectual property protections are not a barrier to access, when compared with the much bigger problem of scarce infrastructure in doctors and hospitals. It also says strong patent protections offer an ‘incentive' for investments in areas such as drug delivery systems suited to conditions of high humidity and temperatures.
Only two years back, the US tried to bridge the gap in the pharmaceutical debate with a plan that sought to establish a ‘TPP access window', which would give greater legal certainty for generic manufacturers, and reduce customs obstacles and duties on medicines. But other TPP countries rebuffed the plan, with the poorest such as Vietnam seen to be most adversely affected.